Clinical Trial Update: Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Vyxeos (daunorubicin/cytarabine liposome) plus venetoclax versus azacitidine plus venetoclax in acute myeloid leukemia patients unfit f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)
• Vyxeos (CPX-351)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: WITHDRAWN